Bristol Myers Squibb has exercised its option under a research collaboration with Dragonfly Therapeutics, Inc, to enter into an exclusive license for a Sixth Trinket Immunotherapy drug candidate, bringing the total drug candidates licensed by BMS to seven including Dragonfly’s novel IL12 cytokine DF6002/BMS-986415. Since their original 2017 collaboration focusing on hematology malignancies, the companies […]

The post BMS, Dragonfly Enter Exclusive License for Sixth TriNKET Immunotherapy Candidate first appeared on World Pharma Today.